UCLA SPORE in Prostate Cancer

描述（由申请人提供）：加州大学洛杉矶分校前列腺癌孢子项目是一个多学科和转化研究项目，其目的是了解前列腺癌的生物学和开发更有效的预防、诊断和治疗方法。这项任务将通过以下方式完成：(1)五个主要研究项目，重点是将基础科学和人口科学应用于前列腺癌的预防、诊断和治疗；(2)通过职业发展和发展研究项目招募和发展新的前列腺癌研究人员和研究项目。加州大学洛杉矶分校前列腺孢子利用加州大学洛杉矶分校令人兴奋的资源和项目，其姐妹机构，以及雪松西奈和希望之城癌症中心，以改善前列腺癌患者的护理。它与其他SPORE机构和NCI的SPORE项目广泛合作，以推进地方和国家倡议。在最初的四年资助中，UCLA SPORE取得了重大进展，例如PSCA抗体疗法的开发和临床转化，mTOR拮抗剂在PTEN阴性肿瘤患者中下调PIS激酶-PTEN- akt通路的分子水平的证明，以及在接受前列腺手术的男性中启动了一项新的饮食预防试验。在本申请中，五个主要项目如下：1)项目1：针对前列腺干细胞抗原的生物工程抗体（PSCA）用于前列腺癌成像（项目负责人：Anna Wu， M.D.和Robert Reiter， M.D.，项目联合负责人Robert Figlin， M.D.）；2)项目2：利用PIS通路抑制剂治疗前列腺癌（项目负责人：Hong Wu， m.d., phd .和Charles Sawyers， m.d.；项目共同负责人，Robert Reiter, m.d.）Howard Scher，医学博士；3)项目3：前列腺癌的淋巴管生成和转移（项目负责人：Lily Wu， M.D., Ph.D；项目联合负责人：David Agus， M.D.）；4)项目4：评估IGFBP-3治疗在男性前列腺癌中的作用（项目负责人：Pinchas Cohen， M.D.；项目共同负责人：Alan Pantuck， M.D.和Kuk-Wha Lee， M.D., ph . 5）项目5：饮食脂肪调节和前列腺癌预防的靶向治疗（项目负责人：William Aronson， M.D.；项目共同负责人：Pinchas Cohen， M.D.和Harvey Herschman， Ph.D）

DESCRIPTION (provided by applicant): The UCLA Prostate Cancer SPORE program is a multidisciplinary and translational research program whose purpose is to understand the biology of prostate cancer and to develop more effective methods for prevention, diagnosis and treatment. This mission will be accomplished through (1) five major research projects focused on the application of basic and population science to the prevention, diagnosis and treatment of prostate cancer, and (2) the recruitment and development of new prostate cancer researchers and research projects through career development and developmental research projects. The UCLA prostate SPORE leverages the exciting resources and programs at UCLA, its sister institutions, as well as Cedars Sinai and City of Hope Cancer Center, to improve the care of men with prostate cancer. It collaborates extensively with other SPORE institutions and the SPORE program at the NCI to advance local and national initiatives. Over the first four years of funding, the UCLA SPORE has made significant strides, such as the development and translation of PSCA antibody therapy to the clinic, the demonstration at the molecular level that mTOR antagonism down-regulates the PIS kinase-PTEN-Akt pathway in men with PTEN null tumors, and the initiation of a novel dietary prevention trial in men undergoing prostate surgery. In this application, the five major projects are as follows: 1) Project 1: Bioengineered Antibodies Against Prostate Stem Cell Antigen (PSCA) for Prostate Cancer Imaging (Project Leaders: Anna Wu, M.D. and Robert Reiter, M.D; Project co-Leader, Robert Figlin, M.D.); 2) Project 2: Exploiting PIS Pathway Inhibitor Therapy in Prostate Cancer (Project Leaders: Hong Wu, M.D, Ph.D. and Charles Sawyers, M.D; Project co-Leaders, Robert Reiter, M..D. and Howard Scher, M.D; 3) Project 3: Lymphangiogenesis and Metastasis in Prostate Cancer (Project Leader: Lily Wu, M.D., Ph.D; Project co-Leader: David Agus, M.D.); 4) Project 4: Evaluating the role of IGFBP-3 therapy in men with prostate cancer (Project Leader: Pinchas Cohen, M.D.; Project co- Leaders: Alan Pantuck, M.D and Kuk-Wha Lee, M.D., Ph.D; 5) Project 5: Dietary Fat Modulation and targeted Therapies for Prostate Cancer Prevention (Project Leader: William Aronson, M.D.; Project co- Leaders: Pinchas Cohen, M.D. and Harvey Herschman, Ph.D.)